[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350949-105":59,"doc-detail-350949-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","age-distribution-of-high-risk-hpv-infection-and-cervical-lesions-in-an-unvaccinated-adult-brazilian-population-within-an-organized-screening-program-research-findings","Age distribution of high-risk HPV infection and cervical lesions in an unvaccinated adult Brazilian population within an organized screening program - Research findings","","High-risk human papillomavirus (hr-HPV) persistent infection is the necessary cause of cervical cancer, yet age-specific prevalence in unvaccinated adult women in Brazil remains insufficiently defined. This population-based study analyzes hr-HPV infection and cervical lesions among 20,398 women aged 25–64 screened in the first round of the PREVENTIVO organized program (2017–2022) using HPV-DNA testing in Indaiatuba. Overall hr-HPV prevalence was 12.8%, with a bimodal age pattern and significant type-specific age declines. CIN2+ rates among hr-HPV positive women and cervical cancer peaks are mapped to older ages, supporting baseline data and discussion of extended screening strategies, including a possible hr-HPV exit test beyond 64.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/age-distribution-of-high-risk-hpv-infection-and-cervical-lesions-in-an-unvaccinated-adult-brazilian-population-within-an-organized-screening-program-research-findings/350949/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/age-distribution-of-high-risk-hpv-infection-and-cervical-lesions-in-an-unvaccinated-adult-brazilian-population-within-an-organized-screening-program-research-findings/350949.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data and screening approach were used to assess hr-HPV and cervical lesions?","Question",{"text":112,"@type":113},"The study used HPV-DNA testing within the PREVENTIVO organized program, screening 20,398 women aged 25–64 in Indaiatuba during the first round from 2017–2022.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the overall hr-HPV prevalence and how did it vary by age?",{"text":117,"@type":113},"Overall hr-HPV prevalence was 12.8%, showing a bimodal age pattern with a first peak at 25–26 years and a smaller second peak at 55–56 years.",{"name":119,"@type":110,"acceptedAnswer":120},"How do CIN2+ rates and cervical cancer peaks relate to age in this population?",{"text":121,"@type":113},"Among hr-HPV positive women, 12.4% had CIN2+ including 29 cervical cancers, with CIN2+ rates ranging roughly from 11–17% at ages 25–49 and cervical cancer peaking at 45–46 years and showing no cases after age 55.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350949,1790870161,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAge distribution of high-risk HPV infection and cervical lesions inan unvaccinated adult Brazilian population within an organized screening program  \nRafaella Moraes Rego, Diama Bhadra Vale, Cirbia Silva Campos, Leandro Vasconcelos, Eduardo Campos, Helena Cunha Lopes Lima, Michelle Garcia Discacciati, Luiz Carlos Zeferino & Julio Cesar Teixeira􀀍  \nHigh-risk human papillomavirus (hr-HPV) persistent infection is the necessary cause of cervical cancer, yet age-specific prevalence patterns in unvaccinated adult women remain insufficiently characterized in Brazil. This population-based study describes the distribution of hr-HPV infection and cervical lesions among 20,398 women aged 25–64 years screened during the first screening round of the PREVENTIVO organized program using HPV-DNA testing in Indaiatuba, Brazil (2017–2022) . Overall hr-HPV prevalence was 12.8%(95% CI: 12.4–13.1), with a bimodal age pattern: a first peak at 25–26 years (26%) and a smaller second peak at 55–56 years (11.2%) . HPV16, HPV18, and 12 other hr-HPV types were detected in 2.63%, 1.01%, and 10.72% of women, respectively, all showing significant age-related declines. Among hr-HPV positive women, 12.4% had CIN2+, including 29 cervical cancers. CIN2 + rates ranged from 11 to 17% between ages 25–49, decreased after, and showed a late HSIL peak at 61 years (8.2%). Cervical cancer peaked at 45–46 years, with no cases after age 55, reflecting the impact of early precursor detection within the program. These findings demonstrate a persistent burden of hr-HPV and high-grade lesions at older ages and provide essential baseline data for monitoring vaccination impact. They also support consideration of extended of screening strategies, including a potential hr-HPV “exit test” beyond age 64.  \nCervical cancer remains a major cause of morbidity and mortality among women, particularly in vulnerable populations or in settings with limited access to healthcare services1–3. In Brazil, the annual estimate for 2023– 2025 is 17,000 new cervical cancer cases and 6,000 deaths4. This cancer arises from persistent cervical infection with oncogenic high-risk human papillomavirus (hr-HPV) . Cervical HPV infection is common among young adults, and although 90% of infections are transient, persistent infection increases the risk of developing precursor lesions and, eventually, cervical cancer. Approximately only 1% of all infections progress to cervical  \n5 6  \ncancer , .  \nEstablished preventive measures include vaccination against the most relevant genotypes, especially HPV16 and HPV18, and regular screening for precursor lesions using cervical samples2,7–9. After decades of relying on cytology (Pap smear), molecular tests for hr-HPV DNA detection have become the standard in several countries8, 10–12.  \nThe global adjusted prevalence of HPV infection among women without cytological abnormalities is estimated at 11.7%(95% CI: 11.6–11.7)12. Rates vary by socioeconomic level and, more recently, by the impact of vaccination introduced in 200713, 14. While countries such as Australia and the United Kingdom report substantial declines in vaccine-type HPV prevalence, regions including Sub-Saharan Africa (24%), Eastern Europa (21.4%) e Latin America (16.1%) still show high rates1,7, 12–14.  \nAge-specific hr-HPV distribution often displays a U-shaped or bimodal pattern, with a first peak in adolescence and young adulthood (25–40%), followed by a decline to baseline levels (5–15%) at ages 35–55 years, and, in some settings, a smaller second peak (15–20%) after age 505, 15–17. This late peak may reflect new  \nDepartment of Obstetrics and Gynecology, University of Campinas (UNICAMP), Campinas, SP 13098-340, Brazil.  \n􀀍 [email: juliotex@unicamp.br](email: juliotex@unicamp.br)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nexposures or reactivation of latent infections, potentially influe","cbCaiunbo7W5jLIo","https://ap.wps.com/l/cbCaiunbo7W5jLIo","pdf",1526232,"English","# Background and rationale\n## Burden of cervical cancer and role of persistent hr-HPV\n# Study setting and population\n## PREVENTIVO organized screening program\n## Participants and HPV-DNA testing\n# Prevalence and age patterns\n## Overall hr-HPV prevalence and bimodal peaks\n## HPV types and age-related declines\n# Cervical lesions and cancer outcomes\n## CIN2+ and HSIL age distribution\n## Cervical cancer peak timing\n# Implications for screening policy\n## Vaccination impact monitoring and possible exit testing","[{\"question\":\"What data and screening approach were used to assess hr-HPV and cervical lesions?\",\"answer\":\"The study used HPV-DNA testing within the PREVENTIVO organized program, screening 20,398 women aged 25–64 in Indaiatuba during the first round from 2017–2022.\"},{\"question\":\"What was the overall hr-HPV prevalence and how did it vary by age?\",\"answer\":\"Overall hr-HPV prevalence was 12.8%, showing a bimodal age pattern with a first peak at 25–26 years and a smaller second peak at 55–56 years.\"},{\"question\":\"How do CIN2+ rates and cervical cancer peaks relate to age in this population?\",\"answer\":\"Among hr-HPV positive women, 12.4% had CIN2+ including 29 cervical cancers, with CIN2+ rates ranging roughly from 11–17% at ages 25–49 and cervical cancer peaking at 45–46 years and showing no cases after age 55.\"}]","Age distribution of high-risk HPV infection and cervical lesions in an unvaccinated adult Brazilian population within an organized screening program - Research findings | PDF",1790091967,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67854f7dccf49f8c0ed5b9a59580536a.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37fb3fc19d96b4318e6576c2f2be0d93.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d51cdc5b9566032aa5bc1191ebdc2eb7.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df1535361dc690e1de83268e3011dd42.webp",980,1287]